Celcuity goes early with its Pfizer cast-off
The company is to start a first-line phase 3 breast cancer trial of gedatolisib, as second-line data approach.
Bicycle has a wobble
Zelenectide looks uncompetitive versus Padcev in bladder cancer, while elsewhere a biomarker strategy beckons.
Elevation brings Synaffix on board in HER3
But the group is going up against the likes of Merck/Daiichi, Bristol Myers Squibb and BioNTech.
SABCS 2024 – Ember-3 dims hopes for Lilly’s SERD
Imlunestrant monotherapy only works in ESR1 mutants, but a Verzenio combo is better in all-comers.
ESMO 2024 – combos could be the way forward for CDK2
Incyte’s first substantial data with INCB123667 are eclipsed by Pfizer’s PF-07104091/atirmociclib combo.
The month ahead: September’s upcoming events
It’s back to school for biotech, with a packed conference schedule.
